
<div id="jpedal" style="overflow: hidden; position: relative; width: 893px; height: 1196px;">
<style type="text/css" >
.t {
	-webkit-transform-origin: top left;
	-moz-transform-origin: top left;
	-o-transform-origin: top left;
	-ms-transform-origin: top left;
	-webkit-transform: scale(0.25);
	-moz-transform: scale(0.25);
	-o-transform: scale(0.25);
	-ms-transform: scale(0.25);
	z-index: 2;
	position:absolute;
	white-space:nowrap;
	overflow:visible;
}
</style>
<style type="text/css" >

#t1_2{left:58px;top:104px;}
#t2_2{left:71px;top:108px;letter-spacing:0.1px;}
#t3_2{left:156px;top:104px;word-spacing:2.8px;}
#t4_2{left:58px;top:122px;word-spacing:7.9px;}
#t5_2{left:58px;top:140px;word-spacing:8.8px;}
#t6_2{left:58px;top:159px;word-spacing:1.9px;}
#t7_2{left:58px;top:177px;letter-spacing:-0.3px;word-spacing:30.1px;}
#t8_2{left:58px;top:195px;letter-spacing:-0.3px;word-spacing:9.7px;}
#t9_2{left:58px;top:213px;letter-spacing:-0.2px;word-spacing:11.4px;}
#ta_2{left:293px;top:212px;}
#tb_2{left:306px;top:213px;letter-spacing:-0.4px;word-spacing:11.7px;}
#tc_2{left:58px;top:232px;letter-spacing:-0.3px;word-spacing:10.3px;}
#td_2{left:58px;top:250px;letter-spacing:-0.3px;word-spacing:9px;}
#te_2{left:58px;top:268px;letter-spacing:-0.3px;word-spacing:25.3px;}
#tf_2{left:58px;top:286px;letter-spacing:-0.3px;word-spacing:17.3px;}
#tg_2{left:58px;top:305px;letter-spacing:-0.2px;word-spacing:24.1px;}
#th_2{left:417px;top:303px;}
#ti_2{left:58px;top:323px;letter-spacing:-0.3px;}
#tj_2{left:141px;top:323px;letter-spacing:-0.4px;}
#tk_2{left:187px;top:323px;letter-spacing:-0.3px;}
#tl_2{left:229px;top:323px;letter-spacing:-0.4px;}
#tm_2{left:324px;top:323px;letter-spacing:-0.4px;}
#tn_2{left:374px;top:323px;letter-spacing:-0.4px;}
#to_2{left:58px;top:341px;letter-spacing:-0.2px;word-spacing:21.9px;}
#tp_2{left:58px;top:359px;letter-spacing:-0.3px;word-spacing:4.9px;}
#tq_2{left:370px;top:358px;}
#tr_2{left:76px;top:378px;letter-spacing:0.1px;word-spacing:11.4px;}
#ts_2{left:58px;top:396px;word-spacing:12.3px;}
#tt_2{left:58px;top:414px;letter-spacing:0.1px;word-spacing:2.7px;}
#tu_2{left:58px;top:433px;word-spacing:3.6px;}
#tv_2{left:58px;top:451px;word-spacing:5.9px;}
#tw_2{left:182px;top:449px;}
#tx_2{left:188px;top:449px;}
#ty_2{left:197px;top:449px;}
#tz_2{left:208px;top:451px;word-spacing:5.9px;}
#t10_2{left:58px;top:469px;word-spacing:1.4px;}
#t11_2{left:58px;top:487px;word-spacing:-0.4px;}
#t12_2{left:58px;top:506px;word-spacing:17.6px;}
#t13_2{left:58px;top:524px;word-spacing:3.8px;}
#t14_2{left:58px;top:542px;word-spacing:15.5px;}
#t15_2{left:58px;top:560px;word-spacing:17px;}
#t16_2{left:58px;top:579px;word-spacing:3px;}
#t17_2{left:58px;top:597px;word-spacing:7.9px;}
#t18_2{left:58px;top:615px;word-spacing:1.6px;}
#t19_2{left:58px;top:634px;letter-spacing:0.1px;word-spacing:7.1px;}
#t1a_2{left:58px;top:652px;word-spacing:8.1px;}
#t1b_2{left:333px;top:650px;}
#t1c_2{left:339px;top:650px;}
#t1d_2{left:348px;top:650px;}
#t1e_2{left:366px;top:652px;word-spacing:7.9px;}
#t1f_2{left:58px;top:670px;word-spacing:17.9px;}
#t1g_2{left:58px;top:688px;word-spacing:21.9px;}
#t1h_2{left:58px;top:707px;word-spacing:5.5px;}
#t1i_2{left:201px;top:705px;}
#t1j_2{left:76px;top:725px;letter-spacing:0.1px;word-spacing:7.5px;}
#t1k_2{left:58px;top:743px;word-spacing:6.4px;}
#t1l_2{left:58px;top:761px;word-spacing:5.2px;}
#t1m_2{left:58px;top:816px;word-spacing:5.6px;}
#t1n_2{left:58px;top:841px;word-spacing:5.3px;}
#t1o_2{left:58px;top:860px;word-spacing:20.7px;}
#t1p_2{left:58px;top:876px;word-spacing:12.6px;}
#t1q_2{left:58px;top:893px;word-spacing:8.4px;}
#t1r_2{left:58px;top:910px;word-spacing:9.7px;}
#t1s_2{left:58px;top:927px;word-spacing:11.2px;}
#t1t_2{left:58px;top:943px;word-spacing:18.6px;}
#t1u_2{left:58px;top:960px;word-spacing:14.7px;}
#t1v_2{left:58px;top:977px;word-spacing:12.3px;}
#t1w_2{left:58px;top:994px;word-spacing:4.2px;}
#t1x_2{left:58px;top:1010px;}
#t1y_2{left:58px;top:1027px;word-spacing:9.1px;}
#t1z_2{left:58px;top:1044px;word-spacing:31.2px;}
#t20_2{left:58px;top:1061px;word-spacing:8.2px;}
#t21_2{left:58px;top:1077px;word-spacing:20.4px;}
#t22_2{left:58px;top:1094px;word-spacing:1.5px;}
#t23_2{left:58px;top:1111px;word-spacing:4px;}
#t24_2{left:58px;top:1128px;word-spacing:4.7px;}
#t25_2{left:478px;top:104px;word-spacing:6.1px;}
#t26_2{left:460px;top:120px;word-spacing:4.2px;}
#t27_2{left:460px;top:137px;word-spacing:15.3px;}
#t28_2{left:460px;top:154px;word-spacing:21.4px;}
#t29_2{left:460px;top:171px;word-spacing:6.4px;}
#t2a_2{left:460px;top:187px;word-spacing:15px;}
#t2b_2{left:460px;top:204px;word-spacing:1.9px;}
#t2c_2{left:460px;top:221px;word-spacing:28.5px;}
#t2d_2{left:460px;top:238px;word-spacing:12.7px;}
#t2e_2{left:460px;top:254px;word-spacing:19.1px;}
#t2f_2{left:460px;top:271px;word-spacing:18.5px;}
#t2g_2{left:460px;top:288px;word-spacing:4.6px;}
#t2h_2{left:478px;top:305px;word-spacing:25.5px;}
#t2i_2{left:460px;top:321px;}
#t2j_2{left:481px;top:321px;}
#t2k_2{left:495px;top:321px;word-spacing:4.1px;}
#t2l_2{left:658px;top:321px;}
#t2m_2{left:671px;top:321px;word-spacing:4.4px;}
#t2n_2{left:703px;top:321px;}
#t2o_2{left:718px;top:321px;word-spacing:4.1px;}
#t2p_2{left:770px;top:321px;}
#t2q_2{left:785px;top:321px;word-spacing:4.1px;}
#t2r_2{left:460px;top:338px;}
#t2s_2{left:488px;top:338px;}
#t2t_2{left:502px;top:338px;word-spacing:3.3px;}
#t2u_2{left:460px;top:355px;word-spacing:10.6px;}
#t2v_2{left:460px;top:372px;word-spacing:5px;}
#t2w_2{left:460px;top:388px;word-spacing:10.7px;}
#t2x_2{left:460px;top:405px;word-spacing:9.8px;}
#t2y_2{left:717px;top:403px;}
#t2z_2{left:734px;top:405px;word-spacing:9.8px;}
#t30_2{left:460px;top:422px;word-spacing:9.7px;}
#t31_2{left:460px;top:439px;word-spacing:2.1px;}
#t32_2{left:460px;top:455px;word-spacing:4.7px;}
#t33_2{left:460px;top:482px;letter-spacing:0.1px;word-spacing:5.1px;}
#t34_2{left:460px;top:500px;word-spacing:1.2px;}
#t35_2{left:460px;top:517px;word-spacing:9.9px;}
#t36_2{left:460px;top:534px;word-spacing:19.3px;}
#t37_2{left:460px;top:551px;word-spacing:11.6px;}
#t38_2{left:460px;top:567px;word-spacing:-0.3px;}
#t39_2{left:460px;top:584px;word-spacing:9.5px;}
#t3a_2{left:703px;top:584px;}
#t3b_2{left:714px;top:584px;word-spacing:9.5px;}
#t3c_2{left:460px;top:601px;}
#t3d_2{left:472px;top:601px;}
#t3e_2{left:483px;top:601px;word-spacing:4.7px;}
#t3f_2{left:460px;top:650px;}
#t3g_2{left:460px;top:669px;letter-spacing:0.1px;word-spacing:2.8px;}
#t3h_2{left:460px;top:688px;letter-spacing:0.1px;word-spacing:21.8px;}
#t3i_2{left:460px;top:706px;word-spacing:29.4px;}
#t3j_2{left:460px;top:724px;letter-spacing:0.1px;}
#t3k_2{left:553px;top:724px;word-spacing:14.3px;}
#t3l_2{left:460px;top:742px;word-spacing:15.5px;}
#t3m_2{left:460px;top:761px;word-spacing:13.6px;}
#t3n_2{left:460px;top:779px;word-spacing:9.6px;}
#t3o_2{left:460px;top:797px;word-spacing:12.1px;}
#t3p_2{left:460px;top:815px;word-spacing:3.8px;}
#t3q_2{left:460px;top:834px;word-spacing:5.3px;}
#t3r_2{left:478px;top:852px;word-spacing:6.1px;}
#t3s_2{left:460px;top:870px;}
#t3t_2{left:504px;top:870px;}
#t3u_2{left:575px;top:870px;letter-spacing:0.1px;}
#t3v_2{left:655px;top:870px;}
#t3w_2{left:678px;top:870px;}
#t3x_2{left:736px;top:870px;}
#t3y_2{left:782px;top:870px;}
#t3z_2{left:812px;top:870px;}
#t40_2{left:460px;top:889px;word-spacing:3.7px;}
#t41_2{left:460px;top:907px;word-spacing:6.7px;}
#t42_2{left:460px;top:925px;word-spacing:1px;}
#t43_2{left:460px;top:943px;word-spacing:15.7px;}
#t44_2{left:460px;top:962px;word-spacing:1px;}
#t45_2{left:460px;top:980px;word-spacing:1.1px;}
#t46_2{left:460px;top:998px;word-spacing:5.3px;}
#t47_2{left:478px;top:1016px;word-spacing:-4px;}
#t48_2{left:460px;top:1035px;word-spacing:3.9px;}
#t49_2{left:770px;top:1035px;}
#t4a_2{left:782px;top:1035px;}
#t4b_2{left:460px;top:1053px;word-spacing:5px;}
#t4c_2{left:460px;top:1071px;}
#t4d_2{left:477px;top:1071px;}
#t4e_2{left:493px;top:1071px;word-spacing:-0.3px;}
#t4f_2{left:460px;top:1089px;word-spacing:32.1px;}
#t4g_2{left:460px;top:1108px;}
#t4h_2{left:477px;top:1108px;}
#t4i_2{left:492px;top:1108px;word-spacing:-2.1px;}
#t4j_2{left:460px;top:1126px;letter-spacing:0.1px;}
#t4k_2{left:58px;top:36px;}
#t4l_2{left:196px;top:36px;word-spacing:4.7px;}

.s7_2{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: BLDFEI-AdvPSNCS-R2;
	color: rgb(0,0,0);
}

.s8_2{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: BLDFFO-AdvPS44A44B2;
	color: rgb(0,0,0);
}

.s14_2{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: BLDFDE-AdvPSA35F2;
	color: rgb(0,0,0);
}

.s3_2{
	FONT-SIZE: 40.6px;
	FONT-FAMILY: BLDFEI-AdvPSNCS-R2;
	color: rgb(0,0,0);
}

.s4_2{
	FONT-SIZE: 40.6px;
	FONT-FAMILY: BLDFFO-AdvPS44A44B2;
	color: rgb(0,0,0);
}

.s11_2{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: BLDFFM-AdvPSSym2;
	color: rgb(0,0,0);
}

.s9_2{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: BLDFDG-AdvP4C4E742;
	color: rgb(0,0,0);
}

.s12_2{
	FONT-SIZE: 60.9px;
	FONT-FAMILY: BLDFEJ-AdvP4C4E512;
	color: rgb(0,0,0);
}

.s1_2{
	FONT-SIZE: 60.9px;
	FONT-FAMILY: BLDFEI-AdvPSNCS-R2;
	color: rgb(0,0,0);
}

.s6_2{
	FONT-SIZE: 60.9px;
	FONT-FAMILY: BLDFDE-AdvPSA35F2;
	color: rgb(0,0,0);
}

.s13_2{
	FONT-SIZE: 60.9px;
	FONT-FAMILY: BLDFDG-AdvP4C4E742;
	color: rgb(0,0,0);
}

.s10_2{
	FONT-SIZE: 36.5px;
	FONT-FAMILY: BLDFEI-AdvPSNCS-R2;
	color: rgb(0,0,0);
}

.s15_2{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: BLDFGP-AdvPSA35B2;
	color: rgb(0,0,0);
}

.s5_2{
	FONT-SIZE: 67px;
	FONT-FAMILY: BLDFDE-AdvPSA35F2;
	color: rgb(0,0,0);
}

.s2_2{
	FONT-SIZE: 42.6px;
	FONT-FAMILY: BLDFEI-AdvPSNCS-R2;
	color: rgb(0,0,0);
}

.v1_2{
	-webkit-transform: scale(0.281, 0.25);
	-ms-transform: scale(0.281, 0.25);
	-moz-transform: scale(0.281, 0.25);
	-o-transform: scale(0.281, 0.25);
}

#form2_1{	border-style:none;	z-index:2;	position: absolute;	left:182px;	top:446px;	width:8px;	height:17px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form2_2{	border-style:none;	z-index:2;	position: absolute;	left:416px;	top:300px;	width:8px;	height:17px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form2_3{	border-style:none;	z-index:2;	position: absolute;	left:196px;	top:446px;	width:8px;	height:17px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form2_4{	border-style:none;	z-index:2;	position: absolute;	left:292px;	top:208px;	width:8px;	height:17px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form2_5{	border-style:none;	z-index:2;	position: absolute;	left:368px;	top:355px;	width:9px;	height:17px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form2_6{	border-style:none;	z-index:2;	position: absolute;	left:332px;	top:646px;	width:9px;	height:17px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form2_7{	border-style:none;	z-index:2;	position: absolute;	left:717px;	top:400px;	width:12px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form2_8{	border-style:none;	z-index:2;	position: absolute;	left:347px;	top:646px;	width:14px;	height:17px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form2_9{	border-style:none;	z-index:2;	position: absolute;	left:200px;	top:701px;	width:14px;	height:17px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form2_10{	border-style:none;	z-index:2;	position: absolute;	left:781px;	top:708px;	width:44px;	height:17px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form2_11{	border-style:none;	z-index:2;	position: absolute;	left:477px;	top:1018px;	width:52px;	height:17px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form2_12{	border-style:none;	z-index:2;	position: absolute;	left:459px;	top:726px;	width:96px;	height:17px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form2_13{	border-style:none;	z-index:2;	position: absolute;	left:594px;	top:708px;	width:173px;	height:17px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}

</style>
<style id="fonts2" type="text/css" >

@font-face {
	font-family: BLDFFO-AdvPS44A44B2;
	src: url("2/fonts/BLDFFO-AdvPS44A44B.woff") format("woff");
}

@font-face {
	font-family: BLDFEJ-AdvP4C4E512;
	src: url("2/fonts/BLDFEJ-AdvP4C4E51.woff") format("woff");
}

@font-face {
	font-family: BLDFEI-AdvPSNCS-R2;
	src: url("2/fonts/BLDFEI-AdvPSNCS-R.woff") format("woff");
}

@font-face {
	font-family: BLDFDG-AdvP4C4E742;
	src: url("2/fonts/BLDFDG-AdvP4C4E74.woff") format("woff");
}

@font-face {
	font-family: BLDFGP-AdvPSA35B2;
	src: url("2/fonts/BLDFGP-AdvPSA35B.woff") format("woff");
}

@font-face {
	font-family: BLDFDE-AdvPSA35F2;
	src: url("2/fonts/BLDFDE-AdvPSA35F.woff") format("woff");
}

@font-face {
	font-family: BLDFFM-AdvPSSym2;
	src: url("2/fonts/BLDFFM-AdvPSSym.woff") format("woff");
}

</style>
<div id="t1_2" class="t s1_2">H</div>
<div id="t2_2" class="t s2_2">YPOGONADISM</div>
<div id="t3_2" class="t s1_2">, which is diagnosed in approximately</div>
<div id="t4_2" class="t s1_2">500,000 men annually in the United States, shows</div>
<div id="t5_2" class="t s1_2">an increasing incidence with age and is character-</div>
<div id="t6_2" class="t s1_2">ized by low serum T and symptoms including loss of</div>
<div id="t7_2" class="t s1_2">libido, erectile dysfunction, depression, lethargy,</div>
<div id="t8_2" class="t s1_2">concentration difFculties, sleep disturbances, osteo-</div>
<div id="t9_2" class="t s1_2">porosis and loss of muscle mass.</div>
<div id="ta_2" class="t v1_2 s3_2">1</div>
<div id="tb_2" class="t s1_2">TTh ameliorates</div>
<div id="tc_2" class="t s1_2">these symptoms in most men. Hypogonadism most</div>
<div id="td_2" class="t s1_2">commonly affects middle-aged or older men, a pop-</div>
<div id="te_2" class="t s1_2">ulation that is also frequently affected by CaP.</div>
<div id="tf_2" class="t s1_2">Thus, these conditions often coexist, especially as</div>
<div id="tg_2" class="t s1_2">RT for CaP is associated with lower serum T.</div>
<div id="th_2" class="t v1_2 s3_2">2</div>
<div id="ti_2" class="t s1_2">However,</div>
<div id="tj_2" class="t s1_2">TTh</div>
<div id="tk_2" class="t s1_2">has</div>
<div id="tl_2" class="t s1_2">historically</div>
<div id="tm_2" class="t s1_2">been</div>
<div id="tn_2" class="t s1_2">contra-</div>
<div id="to_2" class="t s1_2">indicated in men with CaP due to concern that</div>
<div id="tp_2" class="t s1_2">higher serum T would enhance CaP growth.</div>
<div id="tq_2" class="t v1_2 s3_2">3</div>
<div id="tr_2" class="t s1_2">Recent clinical experiences have suggested that</div>
<div id="ts_2" class="t s1_2">TTh is not as risky as once believed in men with</div>
<div id="tt_2" class="t s1_2">CaP. In multiple series in which TTh was offered to</div>
<div id="tu_2" class="t s1_2">men following RP 4 CaP recurrences were observed</div>
<div id="tv_2" class="t s1_2">among 177 cases.</div>
<div id="tw_2" class="t v1_2 s3_2">4</div>
<div id="tx_2" class="t v1_2 s4_2">e</div>
<div id="ty_2" class="t v1_2 s3_2">7</div>
<div id="tz_2" class="t s1_2">However, the safety of TTh in</div>
<div id="t10_2" class="t s1_2">men after RT for CaP is more uncertain, in part due</div>
<div id="t11_2" class="t s1_2">to the small number of reported cases. ±urthermore,</div>
<div id="t12_2" class="t s1_2">TTh in men with CaP following RT may appear</div>
<div id="t13_2" class="t s1_2">more risky than after RP, in part due to the chance</div>
<div id="t14_2" class="t s1_2">of residual CaP after RT, the unknown status of</div>
<div id="t15_2" class="t s1_2">lymph nodes or surgical margins and absent pa-</div>
<div id="t16_2" class="t s1_2">thology data on the entire prostate gland. However,</div>
<div id="t17_2" class="t s1_2">several small studies in a total of 69 patients with</div>
<div id="t18_2" class="t s1_2">CaP treated with TTh following brachytherapy and/</div>
<div id="t19_2" class="t s1_2">or EBRT have revealed transient increases in PSA</div>
<div id="t1a_2" class="t s1_2">but no CaP recurrence or progression.</div>
<div id="t1b_2" class="t v1_2 s3_2">8</div>
<div id="t1c_2" class="t v1_2 s4_2">e</div>
<div id="t1d_2" class="t v1_2 s3_2">11</div>
<div id="t1e_2" class="t s1_2">In addi-</div>
<div id="t1f_2" class="t s1_2">tion, in men with CaP on active surveillance no</div>
<div id="t1g_2" class="t s1_2">signiFcant increases in PSA or CaP progression</div>
<div id="t1h_2" class="t s1_2">have been observed.</div>
<div id="t1i_2" class="t v1_2 s3_2">12</div>
<div id="t1j_2" class="t s1_2">We present our multi-institutional experience of</div>
<div id="t1k_2" class="t s1_2">the effects of TTh on longitudinal CaP outcomes in</div>
<div id="t1l_2" class="t s1_2">hypogonadal men after RT.</div>
<div id="t1m_2" class="t s5_2">MATERIALS AND METHODS</div>
<div id="t1n_2" class="t s6_2">Patient Identifcation and Data Acquisition</div>
<div id="t1o_2" class="t s7_2">We retrospectively reviewed the records of men with</div>
<div id="t1p_2" class="t s7_2">hypogonadism treated with TTh after RT for CaP at a</div>
<div id="t1q_2" class="t s7_2">total of 4 institutions, including Baylor College of Medi-</div>
<div id="t1r_2" class="t s7_2">cine, Men’s Health Boston, University of South ±lorida,</div>
<div id="t1s_2" class="t s7_2">and South Texas Urology and Urologic Oncology. Insti-</div>
<div id="t1t_2" class="t s7_2">tutional review board approval was obtained from all</div>
<div id="t1u_2" class="t s7_2">participating institutions and data sharing agreements</div>
<div id="t1v_2" class="t s7_2">were put in place. RT encompassed EBRT and brachy-</div>
<div id="t1w_2" class="t s7_2">therapy with men in the cohort undergoing EBRT and/or</div>
<div id="t1x_2" class="t s7_2">brachytherapy. Patients underwent RT for CaP from 1994</div>
<div id="t1y_2" class="t s7_2">to 2012 and received TTh between 1999 and 2013. Men</div>
<div id="t1z_2" class="t s7_2">were diagnosed with hypogonadism by hypogonadal</div>
<div id="t20_2" class="t s7_2">symptoms, including low libido, erectile dysfunction and</div>
<div id="t21_2" class="t s7_2">fatigue, as well as by biochemical Fndings, including</div>
<div id="t22_2" class="t s7_2">serum T 350 ng/dl or less, and/or ±T less than 1.5 ng/dl or</div>
<div id="t23_2" class="t s7_2">calculated ±T less than 100 pg/ml. Patients received TTh</div>
<div id="t24_2" class="t s7_2">via gel, injection or subcutaneously implanted pellets.</div>
<div id="t25_2" class="t s7_2">Baseline serum T, ±T, estradiol, sex-hormone binding</div>
<div id="t26_2" class="t s7_2">globulin and PSA were determined before TTh initiation.</div>
<div id="t27_2" class="t s7_2">±ollowup serum hormone values were evaluated every</div>
<div id="t28_2" class="t s7_2">3 to 6 months thereafter. All followup serum values</div>
<div id="t29_2" class="t s7_2">presented correspond to the most recent value available.</div>
<div id="t2a_2" class="t s7_2">±ollowup represents the time from initial presentation</div>
<div id="t2b_2" class="t s7_2">through the most recent followup. Laboratory testing was</div>
<div id="t2c_2" class="t s7_2">performed at the Laboratory for Male Reproductive</div>
<div id="t2d_2" class="t s7_2">Research and Testing, Baylor College of Medicine (LIL</div>
<div id="t2e_2" class="t s7_2">and MK); Tosoh Bioscience, San ±rancisco, California</div>
<div id="t2f_2" class="t s7_2">(AM); LabCorp, Burlington, North Carolina (M±S); or</div>
<div id="t2g_2" class="t s7_2">Quest Diagnostics, Madison, New Jersey (AM and RC).</div>
<div id="t2h_2" class="t s7_2">Men were grouped into risk subgroups, including</div>
<div id="t2i_2" class="t s7_2">low</div>
<div id="t2j_2" class="t s8_2">d</div>
<div id="t2k_2" class="t s7_2">Gl 6 or less, intermediate</div>
<div id="t2l_2" class="t s8_2">d</div>
<div id="t2m_2" class="t s7_2">Gl 3</div>
<div id="t2n_2" class="t s9_2">þ</div>
<div id="t2o_2" class="t s7_2">4 and 4</div>
<div id="t2p_2" class="t s9_2">þ</div>
<div id="t2q_2" class="t s7_2">3, and</div>
<div id="t2r_2" class="t s7_2">high</div>
<div id="t2s_2" class="t s8_2">d</div>
<div id="t2t_2" class="t s7_2">Gl 8 or greater. BCR was deemed to have occurred</div>
<div id="t2u_2" class="t s7_2">if any of certain conditions were met, including 1) PSA</div>
<div id="t2v_2" class="t s7_2">greater than absolute nadir plus 2 ng/ml, 2) PSA greater</div>
<div id="t2w_2" class="t s7_2">than current nadir plus 3 ng/ml or 3) 2 consecutive in-</div>
<div id="t2x_2" class="t s7_2">creases in PSA of 0.5 ng/ml or greater.</div>
<div id="t2y_2" class="t v1_2 s10_2">13</div>
<div id="t2z_2" class="t s7_2">Current nadir</div>
<div id="t30_2" class="t s7_2">was deFned as the lowest PSA before the elevated PSA</div>
<div id="t31_2" class="t s7_2">concerning for BCR. Absolute nadir referred to the lowest</div>
<div id="t32_2" class="t s7_2">PSA during followup.</div>
<div id="t33_2" class="t s6_2">Statistical Analysis</div>
<div id="t34_2" class="t s7_2">Baseline and followup serum values were compared using</div>
<div id="t35_2" class="t s7_2">the Wilcoxon signed rank test. PSAV was calculated by</div>
<div id="t36_2" class="t s7_2">linear regression using at least 3 PSA values during</div>
<div id="t37_2" class="t s7_2">12 months or greater. PSAV was compared across sub-</div>
<div id="t38_2" class="t s7_2">groups with the Kruskal-Wallis and ±isher exact tests. All</div>
<div id="t39_2" class="t s7_2">analyses were performed using SPSS</div>
<div id="t3a_2" class="t s11_2">Ò</div>
<div id="t3b_2" class="t s7_2">, version 21 with</div>
<div id="t3c_2" class="t s7_2">p</div>
<div id="t3d_2" class="t s9_2">±</div>
<div id="t3e_2" class="t s7_2">0.05 considered signiFcant.</div>
<div id="t3f_2" class="t s5_2">RESULTS</div>
<div id="t3g_2" class="t s1_2">We identiFed 98 hypogonadal men with a history of</div>
<div id="t3h_2" class="t s1_2">CaP who underwent RT and were subsequently</div>
<div id="t3i_2" class="t s1_2">started on TTh (supplementary table 1, http://</div>
<div id="t3j_2" class="t s1_2">jurology.com/</div>
<div id="t3k_2" class="t s1_2">). Median age was 70.0 years (range</div>
<div id="t3l_2" class="t s1_2">34 to 85). Of the men 50 (51%) received ADT in</div>
<div id="t3m_2" class="t s1_2">addition to RT for initial CaP management while</div>
<div id="t3n_2" class="t s1_2">the remainder received RT alone. The interval be-</div>
<div id="t3o_2" class="t s1_2">tween ADT cessation and TTh initiation was 5 to</div>
<div id="t3p_2" class="t s1_2">60 months. No individual was receiving ADT at the</div>
<div id="t3q_2" class="t s1_2">time of TTh initiation.</div>
<div id="t3r_2" class="t s1_2">Initial prostate biopsy data were available on 86</div>
<div id="t3s_2" class="t s1_2">men</div>
<div id="t3t_2" class="t s1_2">(87.8%),</div>
<div id="t3u_2" class="t s1_2">including</div>
<div id="t3v_2" class="t s1_2">3</div>
<div id="t3w_2" class="t s1_2">(3.1%)</div>
<div id="t3x_2" class="t s1_2">with</div>
<div id="t3y_2" class="t s1_2">Gl</div>
<div id="t3z_2" class="t s1_2">5,</div>
<div id="t40_2" class="t s1_2">44 (44.9%) with Gl 6, 28 (28.6%) with Gl 7, 7 (7.1%)</div>
<div id="t41_2" class="t s1_2">with Gl 8 and 4 (4.1%) with Gl 9 disease. TTh was</div>
<div id="t42_2" class="t s1_2">started a median of 28.6 months (range 13.8 to 40.4)</div>
<div id="t43_2" class="t s1_2">after RT. The mode of TTh was gels in 65%, in-</div>
<div id="t44_2" class="t s1_2">jections in 24% and pellets in 11%. The median time</div>
<div id="t45_2" class="t s1_2">from TTh initiation to the most recent followup visit</div>
<div id="t46_2" class="t s1_2">was 40.8 months (range 1.5 to 147).</div>
<div id="t47_2" class="t s1_2">Table 1 lists baseline and followup results. Median</div>
<div id="t48_2" class="t s1_2">serum T increased from 209 to 420 ng/dl (p</div>
<div id="t49_2" class="t s12_2">&lt;</div>
<div id="t4a_2" class="t s1_2">0.001)</div>
<div id="t4b_2" class="t s1_2">and median free T increased from 5.9 to 10.7 pg/ml</div>
<div id="t4c_2" class="t s1_2">(p</div>
<div id="t4d_2" class="t s13_2">¼</div>
<div id="t4e_2" class="t s1_2">0.001) at followup. Median serum PSA was 0.08</div>
<div id="t4f_2" class="t s1_2">ng/ml at baseline and 0.09 ng/ml at followup</div>
<div id="t4g_2" class="t s1_2">(p</div>
<div id="t4h_2" class="t s13_2">¼</div>
<div id="t4i_2" class="t s1_2">0.05). Serum estradiol and sex-hormone binding</div>
<div id="t4j_2" class="t s1_2">globulin did not change signiFcantly.</div>
<div id="t4k_2" class="t s14_2">1272</div>
<div id="t4l_2" class="t s15_2">TESTOSTERONE THERAPY AFTER RADIATION THERAPY FOR PROSTATE CANCER</div>

<form>
<input type="button"  tabindex="4"  id="form2_1" name="5 0 R"  pdfFieldName="5 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="2"  id="form2_2" name="3 0 R"  pdfFieldName="3 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="5"  id="form2_3" name="6 0 R"  pdfFieldName="6 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="1"  id="form2_4" name="2 0 R"  pdfFieldName="2 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="3"  id="form2_5" name="4 0 R"  pdfFieldName="4 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="6"  id="form2_6" name="7 0 R"  pdfFieldName="7 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="9"  id="form2_7" name="10 0 R"  pdfFieldName="10 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="7"  id="form2_8" name="8 0 R"  pdfFieldName="8 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="8"  id="form2_9" name="9 0 R"  pdfFieldName="9 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="11"  id="form2_10" name="12 0 R"  pdfFieldName="12 0 R" onclick="window.open('http://jurology.com/','_blank');" style="cursor:pointer;" title="http://jurology.com/" />
<input type="button"  tabindex="13"  id="form2_11" name="14 0 R"  pdfFieldName="14 0 R" onclick="window.location.href='3.html';" style="cursor:pointer;"  title="Page 3" />
<input type="button"  tabindex="12"  id="form2_12" name="13 0 R"  pdfFieldName="13 0 R" onclick="window.open('http://jurology.com/','_blank');" style="cursor:pointer;" title="http://jurology.com/" />
<input type="button"  tabindex="10"  id="form2_13" name="11 0 R"  pdfFieldName="11 0 R" onclick="window.location.href='index.html';" style="cursor:pointer;"  title="Page -1" />

</form>
<div id="pg2Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg2"><object width="893" height="1196" data="2/2.svg" type="image/svg+xml" id="pdf2" style="width:893px; height:1196px; background-color:white; -moz-transform:scale(1); z-index: 0;"></object></div>
<!--[if lt IE 9]><script type="text/javascript">
var divCount = 166;
for (var i = 1; i < divCount; i++) {
    var div = document.getElementById("t" + i.toString(36) + "_2");
    if (div !== null) {
        div.style.top = (div.offsetTop * 4) + "px";
        div.style.left = (div.offsetLeft * 4) + "px";
        div.style.zoom = "25%";
    }
}
</script><![endif]-->

</div>
